The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all‐trans retinoic acid in patients with acute myeloid leukemia
@article{Kuendgen2006TheHD, title={The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all‐trans retinoic acid in patients with acute myeloid leukemia}, author={A. Kuendgen and Mathias Schmid and R. P. Schlenk and S. Knipp and B. Hildebrandt and C. Steidl and U. Germing and R. Haas and H. Dōhner and N. Gattermann}, journal={Cancer}, year={2006}, volume={106} }
Valproic acid (VPA) inhibits histone deacetylase activity and, synergizing with all‐trans retinoic acid (ATRA), achieves differentiation induction of myeloid blast cells in vitro.
Topics from this paper
218 Citations
Will histone deacetylase inhibitors require combination with other agents to fulfil their therapeutic potential?
- Biology, Medicine
- British Journal of Cancer
- 2008
- 78
- PDF
Valproic acid combined with 13-cis retinoic acid and 1,25-dihydroxyvitamin D3 in the treatment of patients with myelodysplastic syndromes.
- Biology, Medicine
- Haematologica
- 2007
- 41
- PDF
Effect of histone deacetylase inhibitor valproic acid on progenitor cells of acute myeloid leukemia.
- Biology, Medicine
- Haematologica
- 2007
- 42
- PDF
Histone Deacetylase Inhibitors and Demethylating Agents: Clinical Development of Histone Deacetylase Inhibitors for Cancer Therapy
- Medicine
- Cancer journal
- 2007
- 52
Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents
- Medicine
- Clinical Epigenetics
- 2013
- 77
- Highly Influenced
Phase I trial of ATRA-IV and depakote in patients with advanced solid tumor malignancies
- Biology, Medicine
- Cancer biology & therapy
- 2010
- 21
Valproic Acid and All-Trans Retinoic Acid: Meta-Analysis of a Palliative Treatment Regimen in AML and MDS Patients
- Medicine
- Oncology Research and Treatment
- 2008
- 31
Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia
- Medicine
- Leukemia
- 2011
- 130
- PDF
References
SHOWING 1-10 OF 59 REFERENCES
Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells
- Biology, Medicine
- The EMBO journal
- 2001
- 1,615
- PDF
Histone Deacetylase Is a Target of Valproic Acid-Mediated Cellular Differentiation
- Biology, Medicine
- Cancer Research
- 2004
- 386
- PDF
Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid.
- Medicine
- Blood
- 2004
- 246
- PDF
Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia.
- Biology, Medicine
- Cancer research
- 2001
- 243
- PDF
Histone deacetylases as therapeutic targets in hematologic malignancies.
- Biology, Medicine
- Current opinion in hematology
- 2002
- 120
The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2
- Biology, Medicine
- The EMBO journal
- 2003
- 461
Histone Deacetylase Is a Direct Target of Valproic Acid, a Potent Anticonvulsant, Mood Stabilizer, and Teratogen*
- Medicine, Chemistry
- The Journal of Biological Chemistry
- 2001
- 1,525
- PDF
Inhibitors of histone deacetylase relieve ETO-mediated repression and induce differentiation of AML1-ETO leukemia cells.
- Biology, Medicine
- Cancer research
- 1999
- 212
- Highly Influential
- PDF